Abnormal glucose tolerance in women with prior gestational diabetes mellitus: a 4-year follow-up study

O'Shea, E.; Awang, Mohd Hazriq; Kgosidialwa, Oratile; Tuthill, Antoinette

doi:10.1007/s11845-022-03005-x

Cited by 5 publications

(4 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, early detection of impaired glucose metabolism in pregnant females may prevent this disease. 18 S Se er ru um m P Pr ro ol la ac ct ti in n a as s a an n E Ea ar rl ly y B Bi io om ma ar rk ke er r…”

Section: Discussionmentioning

confidence: 99%

Serum Prolactin as an Early Biomarker for Detection of Gestational Diabetes Mellitus-An Experience at CMH Quetta

Ahmed

Bashir²,

Lqbal³

et al. 2023

PAFMJ

View full text Add to dashboard Cite

Objective: To determine the association between elevated serum prolactin and the development of gestational diabetes mellitus in the first trimester. Study Design: Prospective longitudinal study. Place and Duration of Study: Pathology Department, Combined Military Hospital, Quetta Pakistan, from Apr 2021 to Mar 2022. Methodology: One hundred and twenty-one patients had a measurement of serum prolactin in the first trimester, along with an oral glucose tolerance test in the second and third trimester, at the Pathology Department Combined Military Hospital Quetta Pakistan. Results: In the study group, serum prolactin levels were raised in 51(42.1%) patients in the first trimester. A total of 44(36.3%) patients with raised serum prolactin had impaired oral glucose tolerance tests. A significant association was found between raised serum prolactin and subsequent development of gestational diabetes mellitus in pregnant females. Conclusion: Serum prolactin can be an important biomarker for early diagnosis and monitoring of gestational diabetes mellitus.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum Prolactin as an Early Biomarker for Detection of Gestational Diabetes Mellitus-An Experience at CMH Quetta

Ahmed

Bashir²,

Lqbal³

et al. 2023

PAFMJ

View full text Add to dashboard Cite

show abstract

“…La mayoría de las pacientes con DMG presentan normoglucemia después del parto; sin embargo, tienen un alto riesgo de DMG recurrente, prediabetes (intolerancia a la glucosa o alteración de la glucosa en ayunas) y un riesgo aumentado de 35 a 60% de desarrollar DM2 durante 10 a 20 años después del embarazo. Las mujeres más vulnerables a presentar una alteración en el metabolismo de glucosa en el postparto son aquellas con historia familiar de DM2, de un grupo étnico de alto riesgo (afroamericanas, latinas, asiáticas), con diagnóstico temprano de DMG, con mayor índice de masa corporal previo al embarazo y en el postparto, que requirieron insulina durante la gestación y que pertenecen a un nivel socioeconómico bajo (40)(41)(42)(43)(44)(45). Por ello, se recomienda evaluar a las mujeres que cursaron con DMG durante el período de 4 a 12 semanas postparto para detectar cualquier anormalidad en los niveles de glucosa a través de una glucosa plasmática de ayuno o de una prueba de tolerancia oral a la glucosa de dos horas con 75g de glucosa Si los valores de glucosa son normales, se recomienda la evaluación de la glucosa cada 1 a 3 años.…”

Section: Diabetes Mellitus Gestacional (Dmg)unclassified

Relación de las alteraciones del sueño con el desarrollo de diabetes mellitus gestacional

Valencia¹,

Acosta-Bustos

Guzmán-Medina

et al. 2022

revbiomed

View full text Add to dashboard Cite

Dormir es una actividad fundamental para la salud, por lo que cuando ocurren alteraciones del sueño aumenta el riesgo de trastornos metabólicos, cardiovasculares, endocrinos y neurológicos. Los cambios anatómicos y la fisiología respiratoria del embarazo afectan el curso normal del sueño, impactando en la salud de la mujer embarazada a tal grado que las alteraciones del sueño durante la gestación se asocian con un mayor riesgo de complicaciones obstétricas como la diabetes mellitus gestacional (DMG). La DMG afecta del 4 al 30% de los embarazos en México y se asocia con complicaciones a corto y largo plazo tanto en la madre como en el neonato. Una serie de estudios recientes proporcionan evidencia de una relación entre la alteración del sueño con el desarrollo de DMG y proponen al estrés oxidativo, la inflamación, la activación del sistema nervioso simpático y la desregulación hormonal como mecanismos subyacentes de dicha relación. Esto pone de relieve la importancia de la alteración del sueño como un factor modificable dirigido a una disminución de la frecuencia de DMG. El objetivo de este trabajo es realizar una revisión descriptiva de los diferentes estudios publicados desde el año 2013 al 2022, que han abordado la relación entre la alteración del sueño con el desarrollo de DMG con énfasis en los mecanismos propuestos. Las bases de datos utilizadas fueron PubMed Central y Scielo, utilizando las palabras clave: trastornos del sueño y diabetes gestacional.

show abstract

“…Women with gestational diabetes mellitus (GDM), defined as “diabetes diagnosed during pregnancy, provided that overt diabetes has been excluded in early pregnancy” ( 1 ), are more likely to develop type 2 diabetes mellitus (T2DM) postpartum ( 2 ). Around 30–50% of all women with GDM develop T2DM within 10 years after their pregnancy ( 3 – 5 ). Previous studies have shown that T2DM can be prevented in this population, by adopting changes in lifestyle and/or by medication ( 6 , 7 ).…”

Section: Introductionmentioning

confidence: 99%

Impact of breastfeeding on risk of glucose intolerance in early postpartum after gestational diabetes

Vanlaer,

Minschart,

Vrolijk

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

AimsTo determine the impact of breastfeeding on the risk of postpartum glucose intolerance in women with gestational diabetes.MethodsSub-analysis of two multi-centric prospective cohort studies (BEDIP-N and MELINDA) in 1008 women with gestational diabetes. Data were collected during pregnancy and at a mean of 12 weeks postpartum. Multivariate logistic regression was used to estimate the effect of breastfeeding on glucose intolerance, with adjustment for ethnicity, education, income, professional activity and BMI.ResultsOf all participants, 56.3% (567) breastfed exclusively, 10.1% (102) gave mixed milk feeding and 33.6% (339) did not breastfeed. Mean breastfeeding duration was 3.8 ± 2.4 and 3.7 ± 2.1 months in the breastfeeding and mixed milk feeding groups (p=0.496). The rate of glucose intolerance was lower in both the breastfeeding [22.3% (126)] and mixed milk feeding [25.5% (26)] groups compared to the no breastfeeding group [29.5% (100)], with an adjusted OR of 0.7 (95% CI 0.5–1.0) for glucose intolerance in the breastfeeding group compared to no breastfeeding group and an adjusted OR of 0.7 (95% CI 0.4–1.2) for the mixed milk feeding group compared to the no breastfeeding group. Postpartum, breastfeeding women had a lower BMI, less often postpartum weight retention, lower fasting triglycerides, less insulin resistance and a higher insulin secretion-sensitivity index-2 than the mixed milk feeding and no breastfeeding group. The mixed milk feeding group was more often from an non-White background, had a lower blood pressure and lower fasting triglycerides compared to the no breastfeeding group.ConclusionsBreastfeeding (exclusive and mixed milk feeding) is associated with less glucose intolerance and a better metabolic profile in early postpartum in women with gestational diabetes.

show abstract

Abnormal glucose tolerance in women with prior gestational diabetes mellitus: a 4-year follow-up study

Cited by 5 publications

References 37 publications

Serum Prolactin as an Early Biomarker for Detection of Gestational Diabetes Mellitus-An Experience at CMH Quetta

Serum Prolactin as an Early Biomarker for Detection of Gestational Diabetes Mellitus-An Experience at CMH Quetta

Relación de las alteraciones del sueño con el desarrollo de diabetes mellitus gestacional

Impact of breastfeeding on risk of glucose intolerance in early postpartum after gestational diabetes

Contact Info

Product

Resources

About